Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy
Clinical medicine. Urology · 2008
DOI: 10.4137/cmu.s718 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical medicine. Urology, 2008. Verfasst von Nagi B Kumar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Purpose
The purpose of this Phase II randomized-controlled trial was to evaluate the safety and effect of administering several doses of lycopene to men with clinically localized prostate cancer, on intermediate endpoint biomarkers implicated in prostate carcinogenesis.
Methods
Forty-five eligible men with clinically localized prostate cancer were supplemented with 15, 30 or 45 mg of lycopene or no supplement from biopsy to prostatectomy. Compliance to study agent, toxicity, changes in plasma lycopene, serum steroid hormones, PSA and tissue Ki-67 were analyzed from baseline to completion of intervention.
Results
Forty-two of forty-five five subjects completed the intervention for approximately 30 days from the time of biopsy until prostatectomy. Plasma lycopene increased from baseline to post treatment in all treatment groups with greatest increase observed in the 45 mg lycopene-supplemented arm compared to the control arm without producing any toxicity. Overall, subjects with prostate cancer had lower baseline levels of plasma lycopene similar to those observed in previous studies in men with prostate cancer. Serum free testosterone decreased with 30 mg lycopene supplementation and total estradiol increased significantly with 30 mg and 45 mg supplementation from baseline to end of treatment, with no significant increases in serum PSA or tissue Ki-67. These changes were not significant compared to the control arm for this sample size and duration of intervention.
Conclusions
Although antioxidant properties of lycopene have been hypothesized to be primarily responsible for its beneficial effects, our study suggests that other mechanisms mediated by steroid hormones may also be involved.
Autor:innen und Institutionen
- Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa Florida.
Förderung
- NCI NIH HHS
Zitieren
APA
Kumar, N. B., Besterman-Dahan, K., Kang, L., Pow-Sang, J., Xu, P., Allen, K., Riccardi, D., & Krischer, J. P. (2008). Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy. Clinical medicine. Urology. https://doi.org/10.4137/cmu.s718
Vancouver
Kumar NB, Besterman-Dahan K, Kang L, Pow-Sang J, Xu P, Allen K, et al. Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy. Clinical medicine. Urology. 2008. doi:10.4137/cmu.s718
BibTeX
@article{Kumar2008,
author = {Kumar, Nagi B and Besterman-Dahan, Karen and Kang, Loveleen and Pow-Sang, Julio and Xu, Ping and Allen, Kathy and Riccardi, Diane and Krischer, Jeffrey P},
title = {Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy},
journal = {Clinical medicine. Urology},
year = {2008},
doi = {10.4137/cmu.s718}
}
EUVIMED